10-Q · April 30, 2026
Molson Coors Beverage Company (TAP) reported Q1 2026 net sales of $2.35 billion and EPS of $0.80, slightly exceeding revenue estimates but falling short of earnings expectations. Notably, the company's Americas segment…
Earnings analysis · 10-Q
TAP earnings analysis
Filed November 5, 2026 · Our reading of the company's report
The latest report
Molson Coors posted Q3 net sales of $2,926.5 million, down 1.6% year over year, with a sharp gross-margin decline driven by lower volume and cost inflation. GAAP EPS improved to $1.45 from $(14.79), but the prior-year…
Read full summary
Molson Coors posted Q3 net sales of $2,926.5 million, down 1.6% year over year, with a sharp gross-margin decline driven by lower volume and cost inflation. GAAP EPS improved to $1.45 from $(14.79), but the prior-year comparison was distorted by $3,645.7 million of goodwill impairment and other asset impairments. Nine-month operating cash flow improved to $1,280.4 million, but cash fell to $602.2 million after debt repayment, capital spending, the $275 million Atomic Brands acquisition and shareholder returns. The filing contains no formal revenue or EPS guidance, while ongoing volume weakness and approximately $130.0 million of expected 2026 Midwest Premium pressure remain significant headwinds.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
Reported figures
- Earnings per share
- $1.45
What stood out
-
Sales declined on lower volume
Net sales were $2,926.5 million, down 1.6% year over year, as financial volume declined 3.0%; price and sales mix contributed 1.8%, partly offsetting the volume and 0.4% currency headwinds.
-
Gross margin compressed materially
Gross profit fell 12.2% to $1,030.4 million. Gross margin was approximately 35.2%, down from approximately 39.5% in the prior-year quarter and 43.6% in 2026 Q2, reflecting cost inflation and higher cost of goods sold per hectoliter, which increased 8.6%.
-
EPS recovered from impairment-distorted loss
Operating income was $390.6 million versus a $3,431.1 million operating loss in the prior-year quarter, which included a $3,645.7 million goodwill impairment. Diluted EPS was $1.45 versus $(14.79), although the comparison is heavily distorted by prior-year impairments.
-
Americas profit normalized
Americas net sales decreased 1.2% to $2,232.8 million, while Americas income before taxes was $320.2 million versus a $(3,345.4) million loss, primarily because the prior year included the $3,645.7 million goodwill impairment and $75.3 million Blue Run impairment.
-
EMEA&APAC returned to profit
EMEA&APAC net sales declined 2.7% to $701.4 million and volume fell 3.0%, but income before taxes improved to $81.8 million from a $(110.4) million loss after cycling the prior-year $198.6 million Staropramen impairment.
-
Cash generation improved year to date
Nine-month operating cash flow increased to $1,280.4 million from $1,243.7 million. Capital expenditures incurred were $381.5 million, implying approximately $898.9 million of nine-month operating cash flow less capital expenditures, while capex declined $23.0 million year over year.
What to watch
-
Broad-based volume pressure
Consolidated financial volume declined 3.0% in Q3 and 3.9% for the first nine months. Management cited lower U.S. core and value-brand volumes, soft U.K. demand, and heightened competition; EMEA&APAC volume fell 3.0% in Q3.
-
Input-cost inflation threatens margins
Cost of goods sold increased 5.3% despite lower volume, and cost of goods sold per hectoliter rose 8.6%. Midwest Premium pricing had an approximately $30.0 million unfavorable Q3 impact and is expected to have an approximately $130.0 million unfavorable 2026 impact versus the prior year.
-
Lower cash after debt repayment
Cash and cash equivalents declined to $602.2 million from $896.5 million at December 31, 2025, following repayment of $2.0 billion of senior notes and CAD 500 million of senior notes, along with capex, dividends, the $275 million Atomic Brands acquisition and share repurchases.
-
Foreign cash concentration
Approximately 87% of cash and cash equivalents was held outside the U.S. as of September 30, 2026, creating potential repatriation, tax and foreign-exchange constraints on liquidity.
-
CDC distribution litigation
Management reported no material changes to the Annual Report risk factors, but CDC is pursuing legal action after certain brand owners sought to terminate distribution agreements; the outcome remains uncertain, although the affected brands represented an immaterial amount of Americas sales and income before taxes.
-
ERP implementation execution risk
The company continues a multi-year ERP implementation; MG&A included costs related to the project, and management stated that future process changes could affect internal controls as implementation progresses.
Management's outlook
The 10-Q provides no quantitative revenue or EPS guidance. Management anticipates Midwest Premium pricing will have an approximately $130 million unfavorable impact on 2026 cost of goods sold versus the prior year, including approximately $30 million in Q3 and $100 million year to date.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.